Related Experiment Video

Updated: Aug 2, 2026

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Increased CD133 expression in bone marrow of myelodysplastic syndromes

J Auberger1, M Dlaska, T Auberger

  • 1Department of Internal Medicine, Divisions of General Internal Medicine and Haematology and Oncology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.

Leukemia Research
|July 26, 2005
PubMed

Insights

This study found increased CD133 positive cells in most myelodysplastic syndromes (MDS) patients, suggesting a role for endothelial progenitor cells (EPCs) in MDS pathogenesis. These cells may contribute to bone marrow capillary formation.

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
  • Endothelial progenitor cells (EPCs) play a crucial role in angiogenesis and vascular repair.
  • CD133 is a cell surface marker used to identify EPCs.

Purpose of the Study:

  • To investigate the expression of CD31, CD34, VEGFR-2, and CD133 in bone marrow of MDS patients.
  • To determine the potential role of EPCs in the pathogenesis of MDS.

Main Methods:

  • Immunohistochemical analysis of fresh frozen bone marrow biopsies.
  • Application of monoclonal antibodies against CD31, CD34, VEGFR-2, and CD133.
  • Comparison of 51 MDS patients with 16 AML patients and 18 controls.

Main Results:

  • Increased CD34 expression and decreased CD31 expression in advanced MDS stages compared to normal bone marrow.
  • Elevated VEGFR-2 expression observed in MDS patients.
  • A significant increase in CD133 positive cells was found in the majority of MDS patients.
  • CD133 positive cells were occasionally observed forming capillary-like structures in bone marrow.

Conclusions:

  • The study identifies an increased presence of CD133 positive cells, indicative of EPCs, in most MDS patients.
  • These findings suggest that EPCs may be involved in the pathophysiology of MDS.
  • The contribution of EPCs to neovascularization in the bone marrow microenvironment of MDS warrants further investigation.

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia06:33

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...